ERBB2 and breast carcinoma: This finding is particularly noteworthy as it highlights their potential action as a promising alternative treatment option that can be used in combination with hormonal chemotherapy to overcome the exerted resistance to trastuzumab and other agents among Her2/neu positive breast cancers.